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Pregnancy-induced gene expression
changes in vivo among women with
rheumatoid arthritis: a pilot study
Dana E. Goin1,2, Mette Kiel Smed3, Lior Pachter2,4, Elizabeth Purdom2, J. Lee Nelson5,6, Hanne Kjærgaard3ˆ,
Jørn Olsen7,8, Merete Lund Hetland9,10, Vibeke Zoffmann3,10, Bent Ottesen3 and Damini Jawaheer1,8,11*
Abstract
Background: Little is known about gene expression changes induced by pregnancy in women with rheumatoid
arthritis (RA) and healthy women because the few studies previously conducted did not have pre-pregnancy
samples available as baseline. We have established a cohort of women with RA and healthy women followed
prospectively from a pre-pregnancy baseline. In this study, we tested the hypothesis that pregnancy-induced
changes in gene expression among women with RA who improve during pregnancy (pregDASimproved) overlap
substantially with changes observed among healthy women and differ from changes observed among women
with RA who worsen during pregnancy (pregDASworse).
Methods: Global gene expression profiles were generated by RNA sequencing (RNA-seq) from 11 women with
RA and 5 healthy women before pregnancy (T0) and at the third trimester (T3). Among the women with RA,
eight showed an improvement in disease activity by T3, whereas three worsened. Differential expression analysis
was used to identify genes demonstrating significant changes in expression within each of the RA and healthy
groups (T3 vs T0), as well as between the groups at each time point. Gene set enrichment was assessed in terms
of Gene Ontology processes and protein networks.
Results: A total of 1296 genes were differentially expressed between T3 and T0 among the 8 pregDASimproved
women, with 161 genes showing at least two-fold change (FC) in expression by T3. The majority (108 of 161
genes) were also differentially expressed among healthy women (q<0.05, FC≥2). Additionally, a small cluster of
genes demonstrated contrasting changes in expression between the pregDASimproved and pregDASworse groups,
all of which were inducible by type I interferon (IFN). These IFN-inducible genes were over-expressed at T3
compared to the T0 baseline among the pregDASimproved women.
Conclusions: In our pilot RNA-seq dataset, increased pregnancy-induced expression of type I IFN-inducible genes
was observed among women with RA who improved during pregnancy, but not among women who worsened.
These findings warrant further investigation into expression of these genes in RA pregnancy and their potential
role in modulation of disease activity. These results are nevertheless preliminary and should be interpreted with
caution until replicated in a larger sample.
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Background
Rheumatoid arthritis (RA) is a systemic inflammatory
disease characterized by inflammation of the joints that
continues to contribute significantly to the global burden
of disease [1]. To date, its etiopathogenesis remains un-
known, and despite major advancements in treatment, a
cure remains elusive. Intriguingly, however, it is well
documented that pregnancy can induce significant
changes in RA disease activity. During pregnancy, 50–
75% of women with RA experience a natural and often
dramatic improvement in disease, whereas others may
worsen or show no change [2–5]. Some pregnancy-
related factors, including maternal-fetal disparity at the
human leukocyte antigen locus [6] and fetal microchi-
merism [7, 8], have been associated with the pregnancy-
induced improvement of RA symptoms. Nonetheless,
the biology of human pregnancy in terms of the overall
systemic changes that it induces, how those may differ
between RA and healthy women, and how the
pregnancy-induced changes may have an impact on RA
remain unknown.
Gene expression studies, more specifically comparison
of gene expression profiles (third trimester vs pre-
pregnancy baseline) from women followed longitudinally
from the pre-pregnancy state to the third trimester, can
provide information about biological changes that are in-
duced during pregnancy. Unfortunately, there have been
no gene expression studies in which women — healthy
or with RA — were studied before they became pregnant
as well as during pregnancy to examine such
pregnancy-induced changes. Only few studies of gene
expression have been conducted in the context of RA
pregnancy, using microarray technology [9–12]. In
these studies, pregnancy-related changes with respect
to the pre-pregnancy state were not examined, due to
pre-pregnancy samples not being available [9–11], or
pregnancy profiles were compared to profiles of unre-
lated non-pregnant women [12].
We have established a cohort of RA and healthy
women enrolled before pregnancy and followed pro-
spectively through pregnancy. Using state-of-the-art
RNA sequencing (RNA-seq) technology, we examined
systemic global gene expression in peripheral blood in a
subset of women from this cohort as a pilot. We previ-
ously identified genes whose expression are modulated
by pregnancy in both RA and healthy women, and we
showed that a few genes are modulated differently in RA
compared to healthy women [13]. We have now used
differential expression analysis to further investigate
pregnancy-induced gene expression patterns and fold-
changes (FCs) in expression within our pilot dataset,
taking into account whether the women with RA im-
proved or worsened during pregnancy. We hypothe-
sized that pregnancy-induced changes in gene
expression among women with RA who improve during
pregnancy may overlap substantially with those ob-
served among healthy women and may differ from
changes among women with RA who worsen during
pregnancy.
Methods
Study subjects
Women with RA and healthy women of Danish descent
were recruited and enrolled in a pregnancy cohort in
Denmark, as previously described [13]. A subset of 20
women with RA and 5 healthy women from this cohort
were included in the pilot dataset. Subjects with RA ful-
filled the 1987 revised American College of Rheumatol-
ogy criteria for RA [14]. The study was approved by the
ethics committee for Region Hovedstaden (Denmark),
the Danish Data Protection Agency, and the Children’s
Hospital Oakland Research Institute Institutional Review
Board. All subjects provided written informed consent
prior to enrollment.
Data
Data collected before pregnancy (T0) and at the third
trimester (T3) were included in the present study.
Therefore, women who had missing data at the T0 base-
line or at T3 (eight women with RA) were excluded
from further analyses. At both time points, the women
with RA were examined by trained study nurses. Dis-
ease activity measures including tender and swollen
joint counts based on a total of 28 joints (TJC28 and
SJC28, respectively) and patient global health (GH)
scores were recorded, and a serum sample was collected
for measurement of C-reactive protein (CRP) levels. Data
on medication use during the 3 months prior to both visits
were also recorded. At each visit, blood samples from the
women with RA and healthy women were collected in
PAXgene RNA tubes (PreAnalytiX, Hombrechtikon,
Switzerland).
Assessment of RA disease activity
RA disease activity was assessed using the Disease Activ-
ity Score based on 28 joints and 4 variables (DAS28-
CRP4, abbreviated henceforth as DAS28), as follows
[15]:
DAS28 ¼ 0:56 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃTJC28p þ 0:28 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃSJC28p 
þ 0:36ln CRP þ 1ð Þð Þ þ 0:014GHþ 0:96
Change in DAS28 from T0 to T3 was calculated as:
ΔDAS28 = DAS28T3 −DAS28T0.
The women with RA were categorized into two sub-
sets: those with negative ΔDAS28 values were consid-
ered to show an improvement in DAS28 score at T3
compared to the T0 baseline (referred to as the
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pregDASimproved subset), whereas those with positive
ΔDAS28 values were included in the “worsened” subset,
referred to as pregDASworse. Any improvement in
DAS28 scores (ΔDAS28 < 0) was used as a surrogate for
improvement in disease activity. This was done to cap-
ture even small changes in disease activity that may cor-
relate with biological changes observed at the gene
expression level. Disease activity categories (remission,
low, moderate, or high) were assessed using previously
defined criteria [16].
Sample processing and bioinformatic analyses
Total RNA was isolated from frozen blood samples, and
barcoded cDNA libraries were prepared as previously
described [13]. Pseudo-alignment of the de-multiplexed
raw sequence reads (FASTQ format) to the Ensembl ref-
erence human GRCh38 transcriptome assembly, and
quantification of transcript abundances was performed
using kallisto (version 0.42.4) [17]. BioMart annotations
were used to combine transcript-level counts into gene-
level estimates. Pseudogenes, genes with no annotations,
and genes with very low read counts (<1 count per
million) in at least 25% of all samples were filtered
out. Any globin genes and ribosomal RNA (rRNA)
transcripts still present were also filtered out. To ad-
just for variable sequencing depths across samples,
the gene-level counts were normalized using the
Trimmed Mean of M values (TMM) algorithm as im-
plemented in the edgeR package (version 3.10.5) [18,
19]. To assess batch effects, normalized gene counts
from each pair of technical replicates were plotted,
and correlations were assessed.
Statistical analyses
Differential gene expression analysis was performed
using edgeR (version 3.10.5) [18] to compare normal-
ized gene-level counts between the T3 and T0 time
points within each group of women (i.e., pregDASim-
proved, pregDASworse and healthy women). A model with
a paired-sample design was used for these within-group
comparisons. Between-group comparisons (pregDASim-
proved vs pregDASworse, and pregDASimproved vs healthy)
at each time point were also performed using differen-
tial expression analyses. A negative binomial distribu-
tion was used to handle the over-dispersion in RNA-
seq gene counts. Differential expression was tested
using generalized linear model (GLM) likelihood ratio
tests. To correct for any batch effects, batch was in-
cluded as a covariate in the model. A q value threshold
of 0.05 was used to assess significance. Because sample
sizes were small, FCs in expression were also used in
the interpretation of results, focusing on genes with at
least a two-fold change in expression from T0 to T3.
Functional analysis
Differentially expressed genes were analyzed for over-
representation of Gene Ontology (GO) categories using
a hypergeometric test implemented in the Web-based
Gene Set Analysis Toolkit (WebGestalt) with a threshold
of at least five genes per category [20]. A significance
threshold of q<0.05 was used to define enrichment.
Functional enrichment of gene sets was examined using
the STRING database of known and predicted interac-
tions among proteins [21, 22].
Results
Study subjects
Of the 12 women with RA who had data at both T0 and
T3, 8 were in the pregDASimproved group and 3 were in
the pregDASworse group. One woman was excluded be-
cause, although she had an increase in DAS28 at T3, she
was in remission at both time points and hence did not fit
into the pregDASworse group. The DAS28 scores of the 11
women included in the analyses are shown in Fig. 1. The
average disease duration among the women with RA was
(mean ± SD) 5.9±4.4 years for pregDASimproved and 8.7
±1.0 years for pregDASworse. The average age at concep-
tion was 30.3±5.7 years for pregDASimproved, 33.2±1.9 years
for pregDASworse, and 31.2±5.7 years for the healthy
women.
Fig. 1 Disease activity before pregnancy and at the third trimester
among the women with rheumatoid arthritis. Disease Activity Scores
based on 28 joints and 4 variables (DAS28-CRP4) are shown for the
eight women who improved during pregnancy (solid lines) and the
three women who worsened (dashed lines), at the pre-pregnancy
baseline and at the third trimester. (The straight lines between
time-points are included for graphical purposes only and do not
imply a linear change in score.)
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Among the eight pregDASimproved women, three did
not take any medications at T0 and only one of these
three women started taking medications by T3 (prednis-
olone + sulfasalazine). The remaining five women were
taking prednisolone and/or sulfasalazine at both time
points; one of them was also on anti-tumor necrosis fac-
tor (anti-TNF) therapy at T0, and another was taking
methotrexate at T0. The three pregDASworse women
were all on anti-TNF therapy and taking prednisolone
and/or sulfasalazine (except for one) at T0; at T3, one
was taking prednisolone + sulfasalazine, one remained
on anti-TNF therapy, and one stopped taking
medications.
Genes differentially expressed between T3 and T0 in the
pregDASimproved subset
A total of 1296 genes showed significant differential
expression between T3 and T0 in the pregDASimproved
subset, of which 161 displayed two-fold or more change
in expression (see Additional file 1). These 161 genes
were enriched in a number of immune-related pathways,
as shown in Table 1. Similar results were obtained when
the woman who was receiving anti-TNF therapy at T0
was excluded from the analysis.
Overlap with genes differentially expressed among
healthy women
A large proportion of the 161 genes that exhibited at
least two-fold change in expression between T3 and T0
among the pregDASimproved women were also differen-
tially expressed among healthy women (q<0.05), mostly
(n=108) with two-fold or more change in expression (see
Additional files 1 and 2), although some (n=33) showed
more modest FCs in expression (1.5≤FC<2.0). In
addition, another 77 genes differentially expressed
(q<0.05) in both the pregDASimproved and healthy groups
showed lower FCs among the pregDASimproved women
(1.5≤FC<2.0) than among the healthy women (FC≥2).
The genes with FC≥2 in both the women with RA and
healthy women were enriched in immune-related path-
ways such as immune system process (q =7.9×10−9),
response to other organism (q =2.7×10−7), and defense
response to bacterium (q =9.3×10−6).
Overlap with genes differentially expressed in the
pregDASworse subset
Of the 161 genes differentially expressed in the pregDA-
Simproved subset, some (n=31) were also differentially
expressed (q<0.05, FC≥2) among pregDASworse women,
with most of these genes overlapping with those differ-
entially expressed among healthy women (n=30) (see
Additional file 2). The FCs in expression from T0 to T3
were correlated between the two RA subsets (Pearson
correlation coefficient r=0.86, p<0.00005).
Differences in genes differentially expressed (T3 vs T0)
between the pregDASimproved and pregDASworse subsets
The remaining 130 genes that were differentially
expressed (T3 vs T0: FC≥2, q<0.05) in our data among
the pregDASimproved women, but not among the preg-
DASworse women, were significantly enriched in several
immune-related GO processes, such as immune system
process (q=4.7×10−10), defense response (q=9.6×10−6), im-
mune response (q=5.0×10−5), and innate immune re-
sponse (q=8.0×10−6), among others (Table 2). Of these
130 genes, 78 were also differentially expressed among
Table 1 Gene Ontology (GO) biological processes enriched in
genes differentially expressed among women with RA who
improved during pregnancy
GO biological process Gene count q value
Immune system process 55 7.9 × 10−14
Response to stress 54 9.1 × 10−6
Defense response 35 1.5 × 10−8
Immune response 34 2.2 × 10−8
Multiorganism process 34 6.7 × 10−6
Response to other organism 27 1.4 × 10−9
Response to biotic stimulus 27 2.9 × 10−9
Innate immune response 22 5.6 × 10−7
Response to bacterium 16 9.0 × 10−6
Erythrocyte differentiation 10 6.5 × 10−7
Of the 161 genes differentially expressed (with FC≥2) between T0 and T3
among pregDASimproved women, several were enriched in GO biological
processes relating to immune functions. (Note: These 161 genes included
some that were also differentially expressed among healthy women and
pregDASworse women.)
Table 2 Gene Ontology biological processes enriched in genes
differentially expressed among women with RA who improved
during pregnancy, but not among those who worsened
GO biological process Gene count q value
Immune system process 43 4.7 × 10−10
Defense response 26 9.6 × 10−6
Immune response 24 5.0 × 10−5
Innate immune response 18 8.0 × 10−6
Response to other organism 17 6.7 × 10−5
Response to biotic stimulus 17 1.0 × 10−4
Hemopoiesis 15 2.0 × 10−4
Homeostasis of number of cells 11 6.9 × 10−6
Myeloid cell differentiation 11 7.1 × 10−5
Erythrocyte differentiation 10 2.5 × 10−7
The 130 genes that were differentially expressed (with FC≥2) between T0 and
T3 among pregDASimproved, but not among pregDASworse women, included
several that were enriched in GO biological processes relating to immune
functions
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healthy women (see Additional files 1 and 2). A com-
parison of the FCs in expression from T0 to T3 within
each of the RA subsets revealed a small cluster of
genes that were significantly over-expressed at T3
among pregDASimproved women and under-expressed
(FC≥2, not significant) among pregDASworse women
(Fig. 2). By T3, mean normalized expression levels of
these genes were higher among the pregDASimproved
women than among the pregDASworse women. Interest-
ingly, all of the genes in this cluster were type I inter-
feron (IFN)-inducible (IFI44, IFI44L, IFIT1, HERC5,
CMPK2, RSAD2, and SIGLEC1). Among these, only the
RSAD2 gene was differentially expressed (under-
expressed) at T3 compared to T0 among healthy
women (q<0.05, FC≥2). A number of other type I IFN-
inducible genes (STAT1, IFI16, IFIT2, IFIT5, IFIH1, and
MX1) also exhibited similar patterns of expression, being
over-expressed at T3 (q<0.05) among pregDASimproved
women, though FCs were more modest (1.5- to 1.9-fold),
and under-expressed among pregDASworse women. The
PLSCR1 gene, which can enhance the type I IFN response,
also showed a significant increase in expression (FC≥2) in
the pregDASimproved women by T3, but no change was ob-
served in the pregDASworse women. Of interest, a compari-
son of normalized expression levels of these genes at T0
between pregDASimproved and healthy women revealed that
some of the IFN signature genes (IFI44, IFI44L, HERC5,
CMPK2, SIGLEC1, and MX1) were significantly under-
expressed in the pregDASimproved subset compared to
healthy women at T0 (q<0.05, FC≥2). However, by T3,
there were no significant differences in expression of these
genes between the two groups of women. The IFN-
inducible genes that were over-expressed at T3 among
pregDASimproved women, but not among in the pregDAS-
worse women, belong to a common functional network, as
shown by known and predicted protein interactions from
the STRING database (Fig. 3). Other than RSAD2, none of
the genes shown in this network were differentially
expressed (T3 vs T0) among healthy women.
Discussion
There have been no previous reports of pregnancy-
induced changes in gene expression in RA or healthy
women from pre-pregnancy to the third trimester,
other than our own published findings from our pilot
RNA-seq dataset [13]. Gene expression changes that
accompany improvement or worsening of RA disease
activity during pregnancy, relative to a pre-pregnancy
baseline, have also not been investigated. Thus, our
findings are novel.
In our data, genes showing similar differential expres-
sion from T0 to T3 in both the pregDASimproved and
pregDASworse women were also similarly differentially
expressed among healthy women, suggesting that these
were normal pregnancy-related changes. The observation
that a cluster of type I IFN-inducible genes demonstrated
contrasting changes in expression from T0 to T3 between
the pregDASimproved and pregDASworse women was particu-
larly interesting. These genes were over-expressed at T3
among the pregDASimproved women, compared to the
T0 baseline, even though at T3 five of the eight pregDASim-
proved women were on corticosteroid therapy, which has
been shown to inhibit type I IFN signaling [23, 24].
Over-expression of IFN-inducible genes has also been
observed in RNA-seq profiles of neutrophils among pa-
tients with juvenile idiopathic arthritis (JIA) who were in
drug-induced remission compared to those with active
disease [25]. Neutrophils appear to be activated during
pregnancy, as reported by us [13] and others [26–28].
However, neutrophil-related genes were over-expressed
in both the pregDASimproved and pregDASworse groups; yet,
levels of the IFN-inducible genes (except IFI27) decreased
from T0 to T3 in the pregDASworse subset (not significantly).
Thus, over-expression of IFN-inducible genes during preg-
nancy among pregDASimproved women may not be due to
Fig. 2 Fold-changes in expression for genes differentially expressed
(third trimester [T3] vs baseline [T0]) among women who improved,
but not among those who worsened. Fold-changes in expression
are plotted for women who improved during pregnancy (y-axis) and
women who worsened during pregnancy (x-axis) only for those
genes that were differentially expressed (T3 vs T0) in the “improved”
group (q<0.05) and not in the “worsened” group. Only genes with
FC≥2 are shown. Fold-changes for genes that were under- expressed
at T3 are shown as negative values. The majority of genes showed
similar expression changes in both groups of women with RA, as
shown by the gray dots around the y = x line (solid line). A small cluster
of genes (black triangles), however, was over-expressed among women
who improved and under-expressed among women who worsened.
Genes in this cluster were IFI44, IFI44L, IFIT1, HERC5, CMPK2, RSAD2,
and SIGLEC1
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neutrophil activation. Of interest, the three women who
worsened during pregnancy were all on anti-TNF
therapy at baseline, and non-responders to anti-TNF
therapy have been reported to produce lower levels of
IFNγ than good responders [29, 30]. Although we
might also expect type I IFN genes to be differentially
expressed in concert with type I IFN-inducible genes,
we found no such evidence in our data.
The significance of the type I IFN signature in the
pregDASimproved subset is not entirely clear. Type I IFNs
appear to have conflicting roles in autoimmune diseases.
Whereas a type I IFN signature in lupus is associated
with active disease [31], it correlates with an alleviation
of symptoms in multiple sclerosis (MS) [32], and IFNβ
therapy has been used successfully to treat patients with
MS [33]. In vitro studies as well as studies of animal
models of arthritis suggest that type I IFN most likely
has a protective role in RA [32, 34], although translation
of the findings from the animal models to treat human
RA using IFNβ therapy has thus far not been successful
[34]. The majority of the IFN-inducible genes identified
in our data were under-expressed in the pregDASimproved
subset compared to healthy women at T0, which may
suggest that expression patterns of these genes in RA
could be deregulated as a consequence of the disease.
Type I IFNs appear to promote down-regulation of pro-
inflammatory cytokines and up-regulation of anti-
inflammatory cytokines in organ-targeted autoimmune
diseases [32, 35]. It is thus possible that the lower levels of
IFN-inducible genes in the pregDASimproved women before
pregnancy may reflect lower systemic IFNβ levels, which
favor a pro-inflammatory state. Furthermore, while ex-
pression levels of the IFN-inducible genes did not change
significantly from T0 to T3 among healthy women, they
changed significantly in the pregDASimproved women, and
by T3, they were no longer differentially expressed be-
tween the two groups (data not shown). These observa-
tions support the notion that increased levels of the IFN-
inducible genes identified in our pilot data may help shift
the immunomodulatory balance to an anti-inflammatory
state during pregnancy. We speculate that specific levels
of these gene products may be crucial to maintaining a
healthy pregnancy, explaining why expression levels at T3
among pregDASimproved women became comparable to
those of healthy women.
Some of the IFN-inducible genes that were over-
expressed at T3 in our data (IFI44, IFI44L, and
SIGLEC1) have been reported to show increased ex-
pression in pregnant RA women compared to unre-
lated non-pregnant RA women [12]. That study found
no association between expression levels of these
genes and disease activity. However, pre-pregnancy
Fig. 3 Network graph showing associations between proteins encoded by genes with contrasting changes in expression from the pre-pregnancy
baseline to the third trimester between RA women who improved and those who worsened. The nodes in the network represent proteins encoded
by genes. The edges represent known as well as predicted interactions between the proteins, suggesting that they are part of a common functional
network. Proteins that were not joined in the network are not shown. Variations at the levels of transcripts or post-translational modification are also
not shown. Nodes with unknown 3D structure are shown by smaller size
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data on both disease activity and expression levels
were not available for comparison with pregnancy
data. Although in the present study we did not test for
associations between expression of IFN-inducible
genes and disease activity, we cannot exclude the pos-
sibility that they may be involved.
The strengths of our study include the availability of
paired time-dependent data from the same women at
both time points. This allowed global gene expression
changes induced by pregnancy to be compared to a pre-
pregnancy baseline, while at the same time controlling
for unmeasured confounders. The use of RNA-seq tech-
nology to assess gene expression was also an advantage
over microarray data. Our study does have some limita-
tions. First, the sample sizes were small, especially for
the women who worsened during pregnancy. However,
the availability of data from the same women before and
during pregnancy, as well as the ethnic homogeneity of
the study population, enabled us to overcome some of
the limitations of having a small sample size. Never-
theless, observations relating to the pregDASworse sub-
set should be interpreted with caution until they can
be replicated in a larger sample. Because samples were
processed in two batches, we used sample replicates in
both batches to assess and mitigate batch effects. We
did not examine changes in proportions of different
cell types in blood samples across time points, because
our goal was to identify overall systemic gene expres-
sion changes resulting either from altered expression
of specific genes or from differences in cell propor-
tions. Although there is a possibility that anti-TNF
and/or other medications may have influenced the re-
sults, the lack of variation in medication use within
each subset of women with RA precluded us from
determining if this was the case. Nevertheless, in the
pregDASimproved group, exclusion of the woman on
anti-TNF therapy did not significantly change the re-
sults, suggesting that the findings were not influenced
by anti-TNF. We did not adjust for dosage and/or spe-
cific medications.
Conclusions
The results from our pilot study suggest that genes
demonstrating significant changes in expression in the
pregDASimproved women, but not the pregDASworse
women, during pregnancy — that is, those showing
similar patterns of expression as in healthy pregnancy
or those among the IFN signature — could be involved
in the natural amelioration of RA. These findings war-
rant further investigations into expression of these
genes in RA pregnancy, but are nevertheless prelimin-
ary, and should be interpreted with caution until repli-
cated in a larger sample.
Additional files
Additional file 1: Table S1. Within-group differential expression results
(T3 vs T0) for the 161 genes that showed significant differential
expression (q<0.05, FC≥2) among the pregDASimproved women. Fold
changes (FCs) in expression, p values (unadjusted), and q values are
shown for each of the three groups of women (i.e., pregDASimproved,
pregDASworse, and healthy women). Given the small sample sizes, we
recommend that the q values be interpreted with caution, especially
among the three pregDASworse women. (PDF 153 kb)
Additional file 2: Figure S1. Numbers of genes differentially expressed
(q<0.05, FC≥2) in the three groups of women. (Note: These numbers are
provided only to give context, given the small sample sizes). (PDF 5 kb)
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